EGFR and lung carcinoma: These complexes exhibited 10-fold higher EGFR-inhibiting activity than the clinically used EGFR inhibitor and anticancer drug gefitinib and potent antiproliferation activity against a panel of tumor cell lines, especially lung cancer.